Real-world delivery rate to third-line chemotherapy in patients with advanced gastric cancer

被引：0
|
作者：
Ueno, Masayuki [1 ]
Doi, Akira [1 ]
Mouri, Hirokazu [1 ]
Yamamoto, Hiroshi [1 ]
Mizuno, Motowo [1 ]
机构：
[1] Kurashiki Cent Hosp, Dept Gastroenterol & Hepatol, Kurashiki, Okayama, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2 - 062
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The real-world data in patients with advanced gastric cancer treated with ramucirumab combination chemotherapy.
    Kimura, Akie
    Sakai, Daisuke
    Kudo, Toshihiro
    Nishida, Naohiro
    Katou, Aya
    Inagaki, Chiaki
    Otsuru, Toru
    Tanaka, Koji
    Miyazaki, Yasuhiro
    Makino, Tomoki
    Takahashi, Tsuyoshi
    Kurokawa, Yukinori
    Yamasaki, Makoto
    Doki, Yuichiro
    Mori, Masaki
    Satoh, Taroh
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [22] Is third-line chemotherapy routine practice in recurrent or metastatic gastric cancer?
    Lee, Hyun Woo
    Choi, Yong Won
    Ahn, Mi Sun
    Kang, Seok Yun
    Choi, Jin-Hyuk
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] A retrospective analysis of third-line treatment in advanced gastric cancer.
    Ishizuka, Yasunobu
    Terazawa, Tetsuji
    Yukami, Hiroki
    Yamaguchi, Toshifumi
    Kuwakado, Shin
    Kii, Takayuki
    Goto, Masahiro
    Higuchi, Kazuhide
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [24] Third line chemotherapy for unresectable advanced gastric cancer
    Hosaka, H.
    Akiya, T.
    Fukai, Y.
    Sano, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 226 - 226
  • [25] Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
    Akitaka Makiyama
    Kohei Arimizu
    Gen Hirano
    Chinatsu Makiyama
    Yuzo Matsushita
    Tsuyoshi Shirakawa
    Hirofumi Ohmura
    Masato Komoda
    Keita Uchino
    Kyoko Inadomi
    Shuji Arita
    Hiroshi Ariyama
    Hitoshi Kusaba
    Yudai Shinohara
    Miyuki Kuwayama
    Tatsuhiro Kajitani
    Hisanobu Oda
    Taito Esaki
    Koichi Akashi
    Eishi Baba
    Gastric Cancer, 2018, 21 : 464 - 472
  • [26] Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
    Makiyama, Akitaka
    Arimizu, Kohei
    Hirano, Gen
    Makiyama, Chinatsu
    Matsushita, Yuzo
    Shirakawa, Tsuyoshi
    Ohmura, Hirofumi
    Komoda, Masato
    Uchino, Keita
    Inadomi, Kyoko
    Arita, Shuji
    Ariyama, Hiroshi
    Kusaba, Hitoshi
    Shinohara, Yudai
    Kuwayama, Miyuki
    Kajitani, Tatsuhiro
    Oda, Hisanobu
    Esaki, Taito
    Akashi, Koichi
    Baba, Eishi
    GASTRIC CANCER, 2018, 21 (03) : 464 - 472
  • [27] Prognostic factor analysis in third-line chemotherapy for elderly patients with metastatic gastric cancer.
    Hasegawa, Hiroko
    Iwasaki, Tetsuya
    Ishihara, Akio
    Sakakibara, Yuko
    Akasaka, Tomohumi
    Nakazuru, Shoichi
    Ishida, Hisashi
    Hirao, Motohiro
    Mita, Eiji
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [28] Comparison of efficacy between immune checkpoint inhibitors and irinotecan-based chemotherapy as third-line treatment for patients with advanced gastric cancer: A Korean real-world multicenter study (KCSG ST22-06)
    Lim, Sung Hee
    Kim, Jae-Joon
    Im, Hyeon-Su
    Han, Hye Sook
    Kim, In-Ho
    Koo, Dong-Hoe
    Cho, Jang Ho
    Maeng, Chi Hoon
    Lee, Min-Young
    Lee, Hyo Jin
    Kim, Jwa Hoon
    Park, Sang Gon
    Jung, Joo Young
    Shin, Seong Hoon
    Kim, Ki Hyang
    Lee, Keun-Wook
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Effectiveness of third-line chemotherapy in recurrent ovarian cancer patients
    Yoshihama, T.
    Chiyoda, T.
    Kataoka, F.
    Nomura, H.
    Iguchi, Y.
    Hashimoto, S.
    Yamagami, W.
    Tominaga, E.
    Susumu, N.
    Tsuda, H.
    Aoki, D.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2015, 36 (04) : 424 - 427
  • [30] A real-world study: Efficacy of the third-line therapy of standard therapy versus rechallenge-chemotherapy in refractory metastatic colorectal cancer
    Xu, X.
    Fu, J.
    Xu, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S49 - S49
12345